Avita Medical filed IPR petition against Patent owned by Renovacare Sciences

Avita Medical Limited filed an IPR (Inter Partes Review) petition against US Patent No. 9,610,430 owned by Renovacare Sciences and request that all claim in the patent should be cancelled.

Avita filed the IPR challenge with the US Patent Trial and Appeal Board (PTAB), which has accepted the petition and will now decide whether the case should come to trial. The IPR process allows a petitioner to challenge the validity of a patent by looking at prior art consisting of patents and printed publications. Avita’s IPR petition has been assigned the Review Number IPR2017‐01243.

Avita CEO, Adam Kelliher said that they believe they have presented a very strong rationale to the PTAB as to why this patent should never have been issued, and thus, they respectfully request that all claims in the ‘430 patent should be cancelled. Avita is a pioneer in the regenerative medicine arena, and they are very protective of their intellectual property rights.